PHAXIAM Therapeutics S.A.
Paris Stock Exchange PHXM.PA
PHAXIAM Therapeutics S.A. Shareholders' Equity for the year ending December 31, 2023: USD 28.27 M
-
PHAXIAM Therapeutics S.A. Shareholders' Equity for the year ending December 31, 2022 was USD 25.13 M, a -3.37% change year over year.
-
PHAXIAM Therapeutics S.A. Shareholders' Equity for the year ending December 31, 2021 was USD 26.01 M, a -19.78% change year over year.
-
PHAXIAM Therapeutics S.A. Shareholders' Equity for the year ending December 31, 2020 was USD 32.42 M, a -66.24% change year over year.
-
PHAXIAM Therapeutics S.A. Shareholders' Equity for the year ending December 31, 2019 was USD 96.02 M, a -42.38% change year over year.
| Date | Shareholders' Equity | Minority Interest | Total Equity | Total Stockholders Equity and Liabilities |
|---|
Don’t Miss A Beat
| CEO | Mr. Thibaut du Fayet |
| IPO Date | May 7, 2013 |
| Location | France |
| Headquarters | 60 Avenue Rockefeller |
| Employees | 68 |
| Sector | Health Care |
| Industries | |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Past 5 years
StockViz Staff
February 7, 2025
Any question? Send us an email